Voyager Therapeutics Inc (VYGR) - Total Liabilities

Latest as of September 2025: $68.49 Million USD

Based on the latest financial reports, Voyager Therapeutics Inc (VYGR) has total liabilities worth $68.49 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VYGR cash flow metrics to assess how effectively this company generates cash.

Voyager Therapeutics Inc - Total Liabilities Trend (2013–2024)

This chart illustrates how Voyager Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Voyager Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Voyager Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Voyager Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
ESSA Bancorp Inc NASDAQ:ESSA	USA	$1.93 Billion
KG Eco Technology Services Co. Ltd KQ:151860	Korea	₩3.45 Trillion
OP Bancorp NASDAQ:OPBK	USA	$2.42 Billion
Jacob Finance And Investments Ltd TA:JCFN	Israel	ILA2.24 Billion
Namyang Dairy KO:003920	Korea	₩99.16 Billion
Bank Amar Indonesia JK:AMAR	Indonesia	Rp2.21 Trillion
Smartbroker Holding AG XETRA:SB1	Germany	€11.54 Million
Vestel Elektronik Sanayi ve Ticaret AS IS:VESTL	Turkey	TL155.67 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Voyager Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Voyager Therapeutics Inc market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	6.19	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.31	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Voyager Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Voyager Therapeutics Inc (2013–2024)

The table below shows the annual total liabilities of Voyager Therapeutics Inc from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	$93.29 Million	-18.85%
2023-12-31	$114.96 Million	+14.58%
2022-12-31	$100.34 Million	+1.55%
2021-12-31	$98.80 Million	-7.89%
2020-12-31	$107.26 Million	-57.98%
2019-12-31	$255.25 Million	+95.47%
2018-12-31	$130.58 Million	+158.96%
2017-12-31	$50.43 Million	-6.00%
2016-12-31	$53.64 Million	-11.16%
2015-12-31	$60.38 Million	+483.52%
2014-12-31	$10.35 Million	+159.87%
2013-12-31	$3.98 Million	--

About Voyager Therapeutics Inc

NASDAQ:VYGR USA Biotechnology

Market Cap

$209.06 Million

Market Cap Rank

#16373 Global

#3703 in USA

Share Price

$3.76

Change (1 day)

+0.80%

52-Week Range

$2.73 - $5.33

All Time High

$31.31